Seelos Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Seelos Therapeutics CEO'su Raj Mehra, Jan2019 tarihinde atandı, in görev süresi 5.58 yıldır. in toplam yıllık tazminatı $ 1.73M olup, şirket hissesi ve opsiyonları dahil olmak üzere 34% maaş ve 66% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.81% ine doğrudan sahiptir ve bu hisseler € 5.38K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 5.6 yıldır.

Anahtar bilgiler

Raj Mehra

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	34.0%
CEO görev süresi	5.6yrs
CEO sahipliği	0.8%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Raj Mehra'un ücretlendirmesi Seelos Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$2m	US$587k	-US$38m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$2m	US$562k	-US$74m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$73m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$16m	US$523k	-US$66m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$4m	US$475k	-US$19m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$709k	US$438k	-US$51m

Tazminat ve Piyasa: Raj 'nin toplam tazminatı ($USD 1.73M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 490.17K ).

Tazminat ve Kazançlar: Raj 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Raj Mehra (64 yo)

5.6yrs

Görev süresi

US$1,726,476

Tazminat

Dr. Raj Mehra, Ph D., J.D., was an Independent Director at Larkspur Health Acquisition Corp. since July 2021 and serves as its Director. He was Chairman of Seelos Therapeutics, Inc & serves as Chief Execut...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Raj Mehra	CEO, Founder	5.6yrs	US$1.73m	0.81% € 5.4k
Michael Golembiewski	Chief Financial Officer	2.9yrs	US$846.67k	0.38% € 2.5k
Anthony Marciano	Chief Communications Officer	5.6yrs	Veri yok	Veri yok
Gopal Krishna	Head of Manufacturing & Technical Operations	no data	Veri yok	Veri yok
Tim Whitaker	Chief Medical Officer	no data	Veri yok	Veri yok
Karen Fusaro	Senior VP & Head of Clinical Operations	1.8yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: NXE0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Margaret Dalesandro	Independent Director	2.9yrs	US$89.72k	0.0051% € 34.0
Richard Pascoe	Independent Chairman	11.4yrs	US$87.72k	0.00077% € 5.1
Brian Lian	Independent Director	5.6yrs	US$105.22k	0% € 0

5.6yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NXE0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

Seelos Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

Founder recently bought €92k worth of stock

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought €51k worth of stock

High number of new and inexperienced directors

Recent updates

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Founder recently bought €92k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought €51k worth of stock

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million.

Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)

New 90-day high: €3.20

New 90-day high: €1.60

Seelos Therapeutics, Inc. Announces Dosing of the First Patients in its Registrational Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior

Seelos Therapeutics Regains Compliance with Minimum Bid Price Requirement

New 90-day high: €1.33

Seelos Therapeutics, Inc. announced that it has received $10 million in funding from The Lind Partners, LLC

New 90-day high: €0.93

Revenue in line with expectations

Seelos Therapeutics, Inc. Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.00335 million.

New 90-day low - €0.56

New 90-day low - €0.70

Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from Russell Microcap Value Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş